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Received June 21, 2011; accepted November 28, 2011AbstractBackground: Droperidol is commonly added to intravenous patient-controlled analgesia (IVPCA) regimens as an antiemetic agent. Although
some studies have demonstrated its safety and efficacy, it is not clear whether adding droperidol to IVPCA infusate without an extra loading dose
can effectively reduce the incidence and severity of postoperative nausea and vomiting (PONV) in real-life clinical settings.
Methods: Patients receiving IVPCA in this retrospective survey were classified into two groups based on their IVPCA regimens. The droperidol
group used morphine 1 mg/mL with droperidol 50 mg/mL, and the non-droperidol group was given morphine 1 mg/mL alone. The incidence and
severity of PONV were compared between the two groups during the 3-day course of IVPCA treatment using logistic regression and ordinal
logistic regression. Propensity score methodology was applied to adjust for potential confounders.
Results: Among the 186 patients enrolled, 94 patients received IVPCAwith droperidol, and 92 patients received a pure morphine solution. There
was no significant difference in patient attributes between the two groups. On the 1st postoperative day, there was no significant difference in
incidence or severity of PONV between the two groups. From the 2nd day onward, the patients in the droperidol group had significantly fewer
and less severe episodes of PONV (relative risk 0.34 and 0.31, respectively). The overall effects of droperidol on PONV and its severity during
the whole IVPCA course were also statistically significant, whether or not adjustment for propensity score was made. However, although
a statistically significant decrease in nausea was observed in the droperidol group after the 1st day, no significant difference in the incidence of
vomiting between the two groups was noted during the study.
Conclusion: A loading dose should be considered on the 1st postoperative day. Our study suggests just how beneficial droperidol can be to
IVPCA users in practical clinical settings, showing that droperidol can reduce with some significance the amount and severity of nausea suffered
by patients postoperatively, even if the frequency of patient vomiting remains unchanged.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Droperidol is a butyrophenone that produces central
nervous system depression and exerts an antiemetic effect by
blocking dopamine D2 receptors in the emetic center in the
chemoreceptor trigger zone.1,2 It was first approved in* Corresponding author. Dr. Kuang-Yi Chang, Department of Anesthesi-
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doi:10.1016/j.jcma.2012.03.003Denmark in 1963 for use with anesthesia in order to limit
postoperative nausea and vomiting (PONV).2 Since the late
1970s, low-dose droperidol (0.625e1.25 mg) has been widely
used to prevent and treat PONV in adults and children.3,4
The management of postoperative pain with intravenous
patient-controlled analgesia (IVPCA) is common in many
hospitals due to its rapid and reliable analgesic effect, avoid-
ance of intramuscular injections, and high patient satisfaction.5
However, opioid-based IVPCA is highly emetogenic, and it
has been reported that as many as two-thirds of patients may
suffer an emetic event without treatment during their IVPCAhinese Medical Association. All rights reserved.
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nation of droperidol and morphine in IVPCA infusate reduces
PONV to a greater extent than a single perioperative dose
does.5,7e9
However, in December 2001, the United States Food and
Drug Administration (FDA) issued a “black box” warning
concerning droperidol and torsades de pointes.10 This move
provoked considerable debate and controversy over the safety
and efficacy of droperidol, and many experts in related fields
challenged the basis of the warning.11e13 In an article written
by Habib and Gan,14 published in May 2008 in Anesthesia and
Analgesia, the authors suggested that there was no convincing
evidence to support allegations of an increased incidence of
arrhythmias with off-label use of droperidol for the manage-
ment of PONV, and thus the black box warning was excessive.
Ludwin and Shafer, however, suggested that the FDA was
justified in placing a warning on a drug that was linked to
potentially harmful adverse effects, although the label should
be clarified.15
Although some clinical trials have proven the efficacy and
safety of low-dose droperidol for management of
PONV,5,9,16,17 the clinical settings vary from study to study,
and it is questionable whether the results from controlled trials
can be satisfactorily generalized to routine clinical practice in
different settings. After reviewing the literature above, we
initiated a month-long clinical investigation in August 2008 to
evaluate the ramifications of discontinuing droperidol in the
IVPCA regimen as a pilot study to confirm whether droperidol
is a necessary adjuvant for IVPCA. To fulfill this purpose, we
compared the incidence of PONV between patients receiving
IVPCA with and without droperidol in a routine clinical
setting. Since the patients were not randomly assigned,
propensity score methodology was applied to adjust for the
possible confounding effects on PONV from other observed
variables. Potentially beneficial effects of droperidol on PONV
corresponding to different baseline incidence rates of PONV
would also be estimated.
2. Methods
This retrospective survey was conducted in our hospital,
a tertiary medical center with PCA service around the clock,
after approval by the Institutional Review Board of Taipei
Veterans General Hospital (VGHIRB No. 96-10-07A). Two
kinds of solution were most frequently used as an IVPCA
regimen. One was a standard solution of morphine 1 mg/mL in
normal saline, and the other was the standard morphine
solution with droperidol 50 mg/mL. The standard loading and
bolus doses of IVPCA are 0.05 and 0.02 mL/kg, respectively,
and the lockout interval was set to between 5 and 8 minutes,
irrespective of whether droperidol was added. The anesthesi-
ologists in charge could further adjust these parameters based
on patient conditions. In the past, in order to reduce the
incidence of nausea and vomiting during the course of IVPCA,
most patients received the solution with droperidol. After
a review of current practices and the literature, we decided to
use only a standard morphine solution without droperidol.The data that are the basis of this study were collected from
July to August 2008. All patients undergoing elective surgery
with an American Society of Anesthesiologists physical status
of IeIII and receiving a postoperative IVPCA regimen for
3 days during this period were included in the analysis. The
enrolled patients were assigned to two treatment groups based
on their date of surgery. Patients recruited in July 2008
received a standard morphine solution with droperidol,
whereas those who enrolled in August 2008 used the standard
morphine solution. Propensity score adjustment was applied to
balance patient characteristics in the two groups. After their
operation, patients were transferred to the recovery room, and
IVPCA was then initiated.
During the 3-day IVPCA course, all recruited patients were
visited at least once per day by the PCA team staff. In the
interview, patients were asked whether they had suffered
nausea and vomiting within the previous 24 hours. If they had
had nausea and vomiting during this period, they were asked
to rate the severity of the nausea and vomiting using the
descriptive terms “mild,” “moderate,” and “severe.” The
patients’ charts were also reviewed for any antiemetic medi-
cation given during the IVPCA course. Patients’ characteris-
tics and factors related to PONV, including history of motion
sickness, smoking, and previous PONV, were also collected
for further analysis.2.1. Statistical analysisThe enrolled patients were classified into droperidol and
non-droperidol groups based on the IVPCA regimen used.
Descriptive statistics were used to evaluate patients’ charac-
teristics and PONV during the 3-day IVPCA course.
Comparisons of continuous and categorical variables between
the droperidol and non-droperidol groups were performed
using an independent t test and c2 test, respectively. The crude
relative risk (RR) of PONV with 95% confidence interval (CI)
for each postoperative day was also estimated. The severity of
PONV between the two groups on each postoperative day was
compared using the ManneWhitney U test.
In order to evaluate the effect of adding droperidol on
PONVon each postoperative day, crude odds ratios (ORs) with
95% CI for PONV were estimated with logistic regression.
The effect of adding droperidol on the severity of patient
PONV on each postoperative day was also assessed using
ordinal logistic regression. Proportional odds assumption was
checked with a Score test.18 The overall effects of adding
droperidol as well as the PONV and its severity during the
whole IVPCA course were estimated with generalized esti-
mating equations. An exchangeable correlation structure was
used to account for the correlation of PONV between distinct
postoperative days.
Since patients recruited in this study were not randomly
assigned, and patient characteristics might have been different
between the two groups, the propensity score method was used
to compensate for the difference and diminished the interac-
tion effect of other variables.19 The propensity score was
obtained by using a logistic regression model, with the
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and all baseline characteristics as independent variables. The
results of the propensity score analysis are presented in
Appendix 1. The propensity score obtained was then used as
the only confounding variable, in association with added or
omitted droperidol, to estimate the effect of droperidol on the
probability of PONV. Because PONV is not a rare event
(< 10%) and the OR may underestimate the RR when it is less
than 1, the propensity score-adjusted ORs were transformed
into RRs using the following equation proposed by Zhang and
Kai20:
RR¼ ORð1P0Þ þ ðP0 ORÞ
where P0 denotes the incidence of PONV among the non-
droperidol group. To assess the potential benefits of adding
droperidol to the IVPCA regimen, the number needed to treat
(NNT) on the distinct postoperative days was also estimated.
A value of p¼ 0.05 was considered statistically significant. All
statistical analyses were conducted with SPSS Statistics 17.0
(SPSS Inc., Chicago, IL, USA).
According to the results of Trame`r and Walder’s meta-
analysis,6 the incidence of nausea and vomiting without anti-
emetic prophylaxis is approximately 50%, which can be
further reduced to approximately 20% with an effective dose
of droperidol. After sample size estimation, we found that at
least 52 patients per group were necessary to show a statisti-
cally significant difference between the droperidol and non-
droperidol groups with a significance level of 0.05 andTable 1
Baseline characteristics of patients.
Droperidol
(n¼ 94)
Number (mean) % (SD
Age (y)
65 y 55 58.5




Weight (kg) (62.9) (13.5)
Height (cm) (160.1) (8.3)
Body mass index (kg/m2) (24.5) (4.6)
ASA class





Upper abdomen 12 12.8
Lower abdomen 36 38.3
Extremities 14 14.9
Malignant disease 36 38.3
History of PONV 9 9.6
Motion sickness 19 20.2
Smoker 17 18.1
Morphine consumption (mg) 47.7 24.7
ASA¼American Society of Anesthesiologists; PONV¼ postoperative nausea anda power of 0.9. The patients recruited into the two groups
numbered substantially in excess of the minimal necessary
sample size.3. Results
There were 186 patients enrolled during the study period.
Among them, 94 patients received IVPCA with droperidol,
and 92 patients received a standard morphine solution. There
was no significant difference in the patients’ attributes
between the two groups; the patients’ characteristics are pre-
sented in Table 1. The mean ages in the droperidol and non-
droperidol groups were 58.2 and 61.2 years, respectively
( p¼ 0.27). Furthermore, surgical types classified by operation
site were not significantly different between the two groups
( p¼ 0.73). On average, patients in the droperidol group were
administered more morphine than those in the non-droperidol
group ( p¼ 0.04). No excessive sedation, extrapyramidal
signs, or symptomatic cardiac arrhythmia was reported in
either group.
Table 2 describes the PONV and its severity in the two
groups for each distinct postoperative day. On the 1st post-
operative day, there was no significant difference in the
symptoms or severity of nausea and vomiting between the two
groups. From the 2nd day onward, the droperidol group had
significantly fewer and less severe symptoms of PONV. The
crude RR for PONVon the 2nd and 3rd postoperative days were
0.34 (95% confidence interval (CI) 0.17, 0.65) and 0.31 (95%
confidence interval (CI) 0.13, 0.74), respectively. It should beNon-droperidol p
(n¼ 92)


























Postoperative nausea and vomiting (PONV) in patients receiving intravenous








(n¼ 94) (n¼ 92)
Number % Number %
Nausea only
Day 1 14 14.9 15 16.3 0.91 0.47, 1.78 0.79
Day 2 2 2.1 16 17.4 0.12 0.03, 0.52 < 0.001
Day 3 4 4.3 16 17.4 0.24 0.09, 0.70 0.004
Vomiting
Day 1 13 13.8 14 15.2 0.91 0.45, 1.83 0.79
Day 2 8 8.5 13 14.1 0.60 0.26, 1.38 0.23
Day 3 2 2.1 3 3.3 0.65 0.11, 3.82 0.63
Combined
Day 1 27 28.7 29 31.5 0.91 0.59, 1.41 0.68
Day 2 10 10.6 29 31.5 0.34 0.17, 0.65 < 0.001
Day 3 6 6.4 19 20.7 0.31 0.13, 0.74 0.004
Antiemetics 7 7.4 14 15.2 0.49 0.21, 1.16 0.09
Odds ratio 95% CI p
Severitya
Day 1 0.83 0.45, 1.54 0.55
Mild 10 10.6 10 10.9
Moderate 11 11.7 7 7.6
Severe 6 6.4 12 13.0
Day 2 0.25 0.11, 0.55 < 0.001
Mild 7 7.4 14 15.2
Moderate 3 3.2 8 8.7
Severe 0 0 7 7.6
Day 3 0.21 0.08, 0.54 0.001
Mild 6 6.4 11 12.0
Moderate 0 0 6 6.5
Severe 0 0 5 5.4
a Odds ratio of PONV severity was assessed with ordinal logistic regression.
Table 3
Propensity score-adjusted effects of droperidol on postoperative nausea and
vomiting (PONV) on distinct postoperative days.
Adjusted OR 95% CI p Corrected RR
Nausea only
Day 1 0.82 0.36, 1.90 0.65 0.85
Day 2 0.10 0.02, 0.46 0.003 0.12
Day 3 0.16 0.05, 0.54 0.003 0.19
Vomiting
Day 1 0.86 0.36, 2.05 0.74 0.88
Day 2 0.41 0.15, 1.10 0.08 0.44
Day 3 1.44 0.19, 10.92 0.72 1.42
Combined
Day 1 0.81 0.42, 1.58 0.54 0.86
Day 2 0.2 0.09, 0.47 < 0.001 0.27
Day 3 0.25 0.09, 0.68 0.007 0.29
Antiemetics 0.46 0.17, 1.26 0.13 0.5
Severitya
Day 1 0.78 0.41, 1.50 0.46 d
Day 2 0.20 0.09, 0.46 < 0.001 d
Day 3 0.18 0.07, 0.49 0.001 d
CI¼ confidence interval; OR¼ odds ratio; RR¼ relative risk.
a OR of PONV severity was assessed with ordinal logistic regression.
Fig. 1. Simulated relative risk (RR) of postoperative nausea and vomiting
(PONV) on the 2nd and 3rd postoperative days of a course of intravenous
patient-controlled analgesia. Propensity score-adjusted odds ratios of PONV
on the 2nd and 3rd postoperative days were used to estimate the corresponding
RRs given a different incidence of PONV among the non-droperidol group.
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on the 2nd and 3rd postoperative days. There was no significant
difference in the incidence of vomiting between the two
groups during the 3-day IVPCA course. The OR for severity of
PONV from ordinal logistic regression analysis on the 2nd and
3rd postoperative days was 0.25 (95% confidence interval (CI)
0.11, 0.55) and 0.21 (95% confidence interval (CI) 0.08, 0.54),
respectively. However, the proportion of antiemetics use was
not significantly different between the two groups (OR¼ 0.5,
95% confidence interval (CI) 0.19, 1.27).
Table 3 shows the propensity score-adjusted OR with its
95% CI for PONV and the corrected RR on distinct post-
operative days. No significant difference in the symptoms or
severity of PONV between the two groups was noted on the 1st
postoperative day after adjusting for the propensity score.
However, the droperidol group had a significantly lower risk of
PONV from the 2nd day onward. The estimated propensity
score-adjusted OR of PONV on the 2nd and 3rd postoperative
days was 0.2 and 0.25, respectively (corrected RR 0.27 and
0.29, respectively). It was also noted that droperidol greatly
reduced the risk of pure nausea on the 2nd and 3rd post-
operative days, but was not able to significantly lower the risk
of vomiting during the 3-day IVPCA course.Fig. 1 presents the estimated RR with respect to various
incidences of PONV among the non-droperidol group on the
2nd and 3rd postoperative days. The RR rose gradually along
with the increasing PONV incidence, given the fixed OR.
Fig. 2 shows the estimated NNT with respect to various inci-
dences of PONV among the non-droperidol group on the 2nd
and 3rd postoperative days. Given the PONV incidence of
31.5% and 20.7% among the non-droperidol group on the 2nd
and 3rd postoperative days, the estimated NNT was 4.3 and
6.8, respectively.
Table 4 illustrates the overall effects of droperidol on
PONV and its severity during the whole IVPCA course as
estimated using the generalized estimating equation. In
general, the effects of droperidol on PONV and its severity
Fig. 2. Simulated number needed to treat (NNT) for postoperative nausea and
vomiting (PONV) on the 2nd and 3rd postoperative days of a course of intra-
venous patient-controlled analgesia. Propensity score-adjusted odds ratios for
PONV on the 2nd and 3rd postoperative days were used to estimate the cor-
responding NNTs given a different incidence of PONV among the non-
droperidol group.
231Y.-M. Kuo et al. / Journal of the Chinese Medical Association 75 (2012) 227e233were statistically significant, regardless of whether or not
adjustment for propensity score was made. Although droper-
idol could significantly lower the incidence of pure nausea
during the whole IVPCA course, it did not reduce the risk of
vomiting among the study participants.
4. Discussion
PONV is a frequent and important complication after
surgery and anesthesia. The etiology of PONV is multifacto-
rial.21 In order to reflect real-life clinical situations, we did not
restrict patient populations or analyze a single type of surgery
as previous studies have done, but instead collected variables
identified in Apfel’s simplified risk score.22 We also extended
the observation period to 3 postoperative days rather than only
1 or 2 – most studies followed patients only for the first 24 or
48 hours postoperatively.5,7e9,16,17,23
After the analyses, several important findings were noted
in our study. First, the effect of droperidol on PONV became
statistically significant from the 2nd postoperative day
onward. There was no significant difference in the incidence
or severity of PONV between the droperidol and non-Table 4
Overall effects of droperidol on postoperative nausea and vomiting (PONV)
during the course of intravenous patient-controlled analgesia.
Crude
OR
95% CI p Adjusted
ORa
95% CI p
Nausea only 0.37 0.19, 0.74 0.005 0.33 0.15, 0.73 0.007
Vomiting 0.73 0.36, 1.46 0.37 0.68 0.31, 1.46 0.32
PONV 0.46 0.27, 0.80 0.006 0.41 0.22, 0.77 0.006
Severity of PONV 0.43 0.25, 0.74 0.002 0.39 0.21, 0.71 0.002
All parameters are estimated using generalized estimating equations.
CI¼ confidence interval; OR¼ odds ratio.
a Propensity score-adjusted.droperidol groups on the 1st postoperative day. Second,
despite the fact that droperidol lowered the incidence and
severity of PONV associated with IVPCA use, it was more
effective in reducing nausea than in preventing vomiting.
Third, the benefits on PONV reduction of adding droperidol
to the IVPCA infusate were enhanced with the increase in the
baseline incidence of PONV. All of these findings have
potential clinical implications that have been further
discussed.
Opioid-based IVPCA administration is associated with
a high incidence of PONV. Droperidol is a highly potent
dopamine D2 antagonist with well-proven antiemetic prop-
erties at an intravenous dose as low as 0.625e1.25 mg.22 The
antiemetic effect of droperidol may be dose-dependent, and
its action may last from 6 to 12 hours.16,24 Therefore, it is
suggested that a repeated bolus of small doses should be
considered to achieve the best antiemetic effect.25,26 The
addition of droperidol to the IVPCA regimen was regarded
as a convenient way to extend its antiemetic effect over
time.6,16
Some studies have accessed the benefit of combining an
initial loading dose of droperidol with a small supplemental
dose of droperidol delivered by an IVPCA device.5,7,9,16,23
Lamond et al have demonstrated that droperidol (0.10 mg/
mL) combined with morphine (1 mg/mL) in the IVPCA
container is the optimal dose for preventing PONV.27 Cule-
bras et al compared droperidol doses of 0, 0.005, and
0.050 mg/mL for morphine IVPCA and concluded that
0.050 mg droperidol per milligram of morphine had an
antiemetic effect.17
Although many studies have demonstrated the antiemetic
efficacy of droperidol on PONV related to IVPCA
use,5,7e9,16,23 we found that the effect of droperidol on PONV
became significant from the 2nd postoperative day onward,
without the use of a droperidol loading dose. This might have
resulted from the fact that neither a preoperative loading dose
of droperidol nor any other prophylactic premedication for
PONV was given in our practical setting. It is also possible
that the cumulative dose of droperidol was insufficient to exert
its antiemetic effect on the 1st postoperative day. In light of the
findings from previous studies,7e9 a single bolus dose of
droperidol greater than 1.0 mg should be considered for the
sake of reducing PONV on the 1st postoperative day among
patients receiving IVPCA.
According to our findings, it seems that the antinausea
efficacy of droperidol was superior to its antivomiting efficacy.
Williams et al have demonstrated a reduction in the incidence
of nausea at 12 hours and a reduction in its severity at both 12
and 24 hours when 100 mg droperidol per milligram IVPCA
morphine was used after a bolus of 2.5 mg at the time of
induction.7 Sharmaand Davies used droperidol 50 mg/mg with
IVPCA morphine, and demonstrated a 50% overall reduction
in the incidence of nausea over 24 hours.9 Klahsen et al
demonstrated that droperidol 40 mg/mg (but not 20 mg/mg
PCA morphine) reduced the severity of postoperative nausea
over the 24-hour observation period,5 and they suggested that
40 mg droperidol per milligram PCA morphine following
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documented to produce a clinical reduction in the severity of
nausea.5
In contrast, the antivomiting efficacy of droperidol was
inconclusive based on the previous studies. A combination of
droperidol and morphine PCA following a bolus dose of
droperidol failed to reduce the incidence of vomiting in three
studies.7,8,23 However, Sharma and Davies, and McKenzie et
al demonstrated a reduction in the incidence of vomiting with
PCA droperidol.9,16 Klahsen et al suggested that a further
reduction in the incidence and frequency of vomiting could
not be attained by adding droperidol to IVPCA morphine.5 A
systemic review speculated that dose-responsiveness could be
seen for the antivomiting effect of droperidol, but doses
beyond 2.5 mg did not further increase its efficacy.25 In our
study, there was a trend toward a decreasing incidence of
vomiting, but there was no significant difference between the
two groups throughout the 3-day observation period. An
insufficient number of subjects may account for this finding
since the antivomiting effect of droperidol may not be as
potent as its antinausea effect.
Another positive contribution resulting from our study is
an estimate of the potential benefit of droperidol on PONV
under various baseline incidences in practical clinical
settings. Given the incidence of PONV among the patients in
our study, the NNT for PONV on the 2nd and 3rd post-
operative days was 6.6 and 5.8, respectively. Compared to
other studies, the baseline incidence of PONV in our study
was relatively low. For populations with a higher incidence
of PONV, the benefit of droperidol on PONV would become
more prominent. For example, for a population with a PONV
risk as high as 50%, NNT for PONV on the 2nd and 3rd
postoperative days would become 3 and 3.3, respectively.
No patient experienced excessive sedation, extrapyramidal
signs, or symptomatic cardiac arrhythmia in our study. During
the 1990s, cases of QT prolongation were linked to the use of
droperidol. As mentioned above, in December 2001, the FDA
issued a black box warning due to the potential of droperidol
to produce serious proarrhythmic effects of. Lischke et al
found dose-related effects of droperidol in prolonging the QT
interval.28 Drug-induced QT prolongation has been reported to
increase the risk of severe adverse cardiovascular events (e.g.,
torsades de pointes).21 White et al,29 Charbit et al,30 and Chan
et al31 suggested that maximum QT prolongation occurs
within the first few minutes after administration of droperidol,
and then recovers to baseline. However, a number of drugs
routinely used in anesthesia may also prolong the QTc
interval, including thiopental, isoflurane, sevoflurane, des-
flurane, succinylcholine, neostigmine, atropine, and glyco-
pyrrolate.14,32 Cardiac arrhythmias and QTc prolongation have
also been reported after administration of the 5-HT3 receptor
antagonists,12,33,34 which have largely replaced droperidol for
PONV management.
Droperidol in antiemetic doses has been used safely for over
30 years. Low-dose droperidol (0.625e1.25 mg intravenously)
has been widely accepted as the most cost-effective therapy for
the prophylaxis and/or treatment of PONV.35e38 There is noconvincing evidence to suggest an increased incidence of
arrhythmias when droperidol is used for the management of
PONV.14 Moderately large doses of droperidol (0.5e1 mg/kg
intravenously) have been used in neuroleptic anesthesia for
many years, without any reports of serious cardiac arrhythmias
during the perioperative period.39 Some time later, the FDA
clarified that the black box warning applies only to high-dose
droperidol (> 2.5 mg), as the risk of prolonged QT and
torsades de pointes is not clear at lower doses.40
Clinicians should exercise medical common sense and use
drugs according to their own medical judgment. Continuing 12-
lead electrocardiogram monitoring for all patients receiving
IVPCA is clinically impractical, but should be reserved for those
with a high risk for QTc interval prolongation. Although none of
the studies continuously monitored the ECG to detect the exact
time of return of QTc to baseline, ECGs performed between 90
minutes and 2 hours after administration of droperidol
confirmed the recovery of QTc to baseline.14,29e31 In our
hospital, postoperative ECG monitoring was essential in the
recovery room (on average a 2-hour duration for uncomplicated
cases). Particular caution should be taken under certain condi-
tions where there is an increased risk of arrhythmia, such as
documented QTc prolongation, bradycardia, hypothermia,
hypokalemia, or female patients,30 and droperidol-free IVPCA
should be considered, or at least 2e3-hour ECG monitoring
should be performed, in response to the FDAblack boxwarning.
There are some limitations to our study. First, patients were
not randomly assigned to the two treatment groups. Although
propensity score methodology was applied, it only adjusted for
observable confounders instead of unobservable ones. Second,
given the limited sample size, it is not reasonable to conclude
whether adding droperidol would reduce IVPCA-induced
vomiting. Third, the RR of PONV and NNT of droperidol
under various baseline incidences of PONV were estimated by
imputation processes based on the results of our study, instead
of estimates obtained from real data analyses. Further vali-
dation is necessary to demonstrate the value of adding dro-
peridol in IVPCA.
In conclusion, droperidol 0.05 mg/mg in IVPCA morphine
effectively reduced the incidence and severity of PONV on
the 2nd and 3rd postoperative days, and a loading dose should
be considered on the 1st postoperative day. The antinausea
efficacy of droperidol was superior to its antivomiting effi-
cacy, and no symptomatic cardiac arrhythmia was docu-
mented during the course of IVPCA. Although droperidol in
antiemetic doses has a long safety record, caution should be
taken when droperidol is administered to high-risk patients.
Our study provided valuable information regarding the effect
of droperidol on PONV induced by IVPCA in practical
clinical settings.
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Appendix 1
The results of propensity score analysis.
OR 95% CI p
Age (> 65 vs  65 y) 0.58 0.29 1.15 0.12
Gender (female vs male) 0.84 0.58 1.22 0.37
Weight 1.03 1.00 1.06 0.06
Height 0.94 0.90 0.98 0.002
ASA class ( 3 vs < 3) 1.15 0.51 2.59 0.73
Surgical site 0.41
Spine 0.51 0.08 3.22 0.48
Chest 1.25 0.43 3.60 0.68
Upper abdomen 1.82 0.60 5.58 0.29
Lower abdomen (reference group) d d d d
Spine 2.35 0.90 6.12 0.08
Malignant disease 2.13 0.88 5.17 0.09
history of PONV 1.65 0.49 5.56 0.42
Motion sickness 0.61 0.28 1.34 0.22
Smoker 2.25 0.90 5.59 0.08
ASA ¼ American Society of Anesthesiologists; CI ¼ confidence interval;
OR ¼ odds ratio; PONV ¼ postoperative nausea and vomiting.
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